-
Soaring +11% In Pre-Market, Rigel Receives Buy Initiation Amid Fostamatinib Phase 3 Optimism
Wednesday, July 13, 2016 - 9:24am | 285Read More...The first Phase 3 trials for Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL)'s Syk inhibitor are expected to be announced in August as many investors and analysts prepare for the results. H.C. Wrainwright's Positive Take On Phase 3 H.C. Wainwright & Co's Shaunak Deepak initiated Rigel...
-
Piper Jaffray Provides Color on Biotechnology
Monday, June 27, 2011 - 6:49am | 109Read More...Piper Jaffray provided color on biotechnology. In a research report published today, Piper Jaffray commented on two new drugs, Novo Nordisk's degludec and BMS and AstraZeneca's dapagliflozin. In the report, Piper Jaffray states, “We attended the American Diabetes Association conference, where...
